Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2025-04-04 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ENHERTU APPROVED IN EU IN POST-ET BREAST CANCER
Foreign Filer Report
2025-04-04 English
Imfinzi approved in EU for AEGEAN
Regulatory Filings Classification · 1% confidence The document is an official regulatory announcement (RNS) from AstraZeneca regarding the European Commission's approval of a new medical indication for their drug 'Imfinzi'. It details the clinical trial results (AEGEAN trial), the regulatory context, and the strategic impact on the company's oncology portfolio. As it is a formal regulatory announcement of a specific corporate/product development event rather than a financial report, investor presentation, or management report, it falls under the 'Regulatory Filings' category.
2025-04-04 English
Enhertu approved in EU in post-ET breast cancer
Regulatory Filings Classification · 1% confidence The document is a press release from AstraZeneca announcing the European Union approval of their drug 'Enhertu'. It details the clinical trial results (DESTINY-Breast06), the regulatory approval status, and the financial implications (milestone payments). This type of corporate announcement regarding product development, regulatory milestones, and business operations is classified as a Regulatory Filing (RNS) within the provided schema, as it does not fit into specific categories like Earnings Release (which would focus on quarterly financial results) or Annual Report.
2025-04-04 English
TOTAL VOTING RIGHTS
Foreign Filer Report
2025-04-01 English
Total Voting Rights
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement from AstraZeneca PLC regarding its total voting rights and issued share capital, filed in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. While it mentions capital, it is a standard regulatory disclosure of voting rights rather than a capital raising or financing event. As it is a routine regulatory notification that does not fit into specific categories like DVA (which is for results of votes) or SHA (which is for new share issues), it falls under the RNS (Regulatory Filings) category.
2025-04-01 English
CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCL
Foreign Filer Report
2025-03-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.